| Literature DB >> 26323840 |
Young Ran Ha1, Bae-Geun Hwang2, Yeonchul Hong3, Hye-Won Yang3, Sang Joon Lee2.
Abstract
The parasite Plasmodium falciparum causes severe malaria and is the most dangerous to humans. However, it exhibits resistance to their drugs. Farnesyltransferase has been identified in pathogenic protozoa of the genera Plasmodium and the target of farnesyltransferase includes Ras family. Therefore, the inhibition of farnesyltransferase has been suggested as a new strategy for the treatment of malaria. However, the exact functional mechanism of this agent is still unknown. In addition, the effect of farnesyltransferase inhibitor (FTIs) on mitochondrial level of malaria parasites is not fully understood. In this study, therefore, the effect of a FTI R115777 on the function of mitochondria of P. falciparum was investigated experimentally. As a result, FTI R115777 was found to suppress the infection rate of malaria parasites under in vitro condition. It also reduces the copy number of mtDNA-encoded cytochrome c oxidase III. In addition, the mitochondrial membrane potential (ΔΨm) and the green fluorescence intensity of MitoTracker were decreased by FTI R115777. Chloroquine and atovaquone were measured by the mtDNA copy number as mitochondrial non-specific or specific inhibitor, respectively. Chloroquine did not affect the copy number of mtDNA-encoded cytochrome c oxidase III, while atovaquone induced to change the mtDNA copy number. These results suggest that FTI R115777 has strong influence on the mitochondrial function of P. falciparum. It may have therapeutic potential for malaria by targeting the mitochondria of parasites.Entities:
Keywords: Plasmodium falciparum; farnesyltransferase inhibitor; malaria; mitochondria; mtDNA
Mesh:
Substances:
Year: 2015 PMID: 26323840 PMCID: PMC4566515 DOI: 10.3347/kjp.2015.53.4.421
Source DB: PubMed Journal: Korean J Parasitol ISSN: 0023-4001 Impact factor: 1.341
Fig. 1.Effect of 3 antimalarial drugs on the proliferation of P. falciparum. (A) Proliferation assay of FTI R155777-treated P. falciparum for 48 hr and corresponding Giemsa staining. (B) Proliferation assay of chloroquine-treated P. falciparum and Giemsa staining. (C) Proliferation assay of atovaquone-treated P. falciparum and Giemsa staining.
Fig. 2.Analysis of mitochondrial membrane potential (ΔΨm) after 48 hr of FTI R115777 treatment using the potential-dependent aggregate-forming lipophilic cation JC-1 (5, 5´, 6, 6´-tetrachloro-1, 1´, 3, 3´-tetraethylbenzimidazole carbocyanide iodide). (A) JC-1 staining. Red fluorescence represents mitochondria with intact membrane potential, whereas green fluorescence indicates de-energized mitochondria. (B) JC-1 red/green fluorescence intensity. (C) Immunofluorescence analysis of FTI R115777-treated P. falciparum cells for 48 hr stained with MitoTracker green. (D) Fluorescence intensity of MitoTracker green in FTI R115777-treated P. falciparum. Bars denote SD. *P<0.05.
Fig. 3.Variations in oxygen concentration and ROS production in FTI R115777-treated P. falciparum. (A) Oxygen gradient of FTI R115777-treated P. falciparum on the sensor foil. (B) Variation in oxygen level of FTI R115777-treated P. falciparum. (C) Variation in intercellular ROS level in FTI R115777-treated P. falciparum. Bars denote SD. *P<0.05.
Fig. 4.Variation in copy number determined by PCR for mitochondrial cytochrome c oxidase III. (A, B) Copy number of mtDNA cytochrome c oxidase III in FTI R115777-treated P. falciparum. (C, D) Copy number of mtDNA cytochrome c oxidase III in chloroquine-treated P. falciparum. (E, F) Copy number of mtDNA cytochrome c oxidase III in atovaquone-treated P. falciparum.